-
公开(公告)号：US20080058429A1
公开(公告)日：2008-03-06
申请号：US10545455
申请日：2004-02-13
CPC分类号： G01N33/6893 , G01N2333/904 , G01N2500/10 , G01N2800/168
摘要： The invention provides methods for diagnosing patients with primary open angle glaucoma (POAG), as well as methods for identifying agents for use in treating POAG and methods of using such agents in prevention and treatment of the disease.
摘要翻译： 本发明提供用于诊断原发性开角型青光眼（POAG）患者的方法，以及用于鉴定用于治疗POAG的药剂的方法以及在预防和治疗疾病中使用这些药剂的方法。
-
2.发明授权Use of decreased 3-alpha-hydroxysteroid dehydrogenase activity in peripheral lymphocytes or other cells of patients with primary open angle glaucoma as a diagnostic indicator 失效在原发性开角型青光眼患者的外周淋巴细胞或其他细胞中使用降低的3-α-羟基类固醇脱氢酶活性作为诊断指标
公开(公告)号：US5376534A
公开(公告)日：1994-12-27
申请号：US169611
申请日：1993-12-17
CPC分类号： G01N33/5091 , C12Q1/32 , Y10S435/81 , Y10S435/975 , Y10S436/808 , Y10S514/912 , Y10S514/913
摘要： An assay for determining patients either having Primary Open Angle Glaucoma or at risk of developing Primary Open Angle Glaucoma. The assay involves testing cells, preferably lymphocyte cells, for 3.alpha.-HSD activity and determining from the level of assayed activity whether the patient is either suffering from Primary Open Angle Glaucoma or at risk therefor.
摘要翻译： 用于确定患有原发性开角型青光眼或存在发展为原发性开角型青光眼的风险的患者的测定法。 该测定包括测试细胞，优选淋巴细胞，以获得3α-HSD活性，并根据测定的活性水平确定患者是患有原发性开角型青光眼还是患有风险。
-
公开(公告)号：US4997826A
公开(公告)日：1991-03-05
申请号：US396072
申请日：1989-08-21
IPC分类号： A61K31/57
CPC分类号： A61K31/57 , Y10S514/913 , Y10S514/914
摘要： Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.
摘要翻译： 公开了包含四氢皮质醇的药物组合物及其在控制眼压中的使用方法。
-
公开(公告)号：US06420165B1
公开(公告)日：2002-07-16
申请号：US09577640
申请日：2000-05-24
IPC分类号： B09B300
CPC分类号： C12R1/07 , C02F3/34 , Y10S435/832
摘要： A biologically pure culture of a microorganism is provided designated SH2A and deposited under ATCC Accession No. 55926, or a mutant derived therefrom. Further provided is a biologically pure culture of a microorganism designated SH2B and deposited under ATCC Accession No. 202050, or a mutant derived therefrom. A method of degrading an organic material such as sludge is carried out by treating the organic material with an effective, degrading amount of either SH2A or a mutant derived therefrom, or SH2B or a mutant derived therefrom. The microorganism designated SH2A or a mutant derived therefrom, or SH2B or a mutant derived therefrom, is grown by culturing the microorganism at a temperature and in a medium effective to promote growth of the microorganism.
摘要翻译： 提供微生物的生物学纯培养物，命名为SH2A，保藏于ATCC保藏号55926，或由其衍生的突变体。 进一步提供了一种生物学纯的指定为SH2B并保藏于ATCC保藏号为202050的微生物或其衍生的突变体的培养物。 通过用有效降解量的SH2A或其衍生的突变体或SH2B或其衍生的突变体处理有机材料来进行有机材料如污泥的降解方法。 通过在有效促进微生物生长的温度和介质中培养微生物来生长称为SH2A或其衍生物的突变体或SH2B或其衍生的突变体。
-
公开(公告)号：US4863912A
公开(公告)日：1989-09-05
申请号：US864610
申请日：1986-05-19
CPC分类号： A61K31/57 , Y10S514/913 , Y10S514/914
摘要： Pharmaceutical compositions comprising tetrahydrocortisol and method of using same in the control of intraocular pressure are disclosed.
摘要翻译： 公开了包含四氢皮质醇的药物组合物及其在控制眼压中的使用方法。
-
-
-
-
搜索结果
5 条记录 (耗时 0.018 秒)